
Maze Therapeutics Announces Positive Phase 1 Results for MZE829 in APOL1 Kidney Disease
Maze Therapeutics, a biopharmaceutical company focused on developing precision medicines using human genetics, has announced positive results from the Phase 1 clinical trial of MZE829 in healthy volunteers. MZE829 is…












